

# MARKET REPORT



## Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Inhibitors -Pipeline Insights, 2017

**BioPortfolio**  
Life Science Healthcare and  
Pharmaceutical  
Market Research and  
Corporate Data



# Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Inhibitors -Pipeline Insights, 2017

BioPortfolio has been marketing business and market research reports from selected publishers for over fifteen years. BioPortfolio offers a personal service to our customers with dedicated research managers who will work with you to source the best report for your needs. Based in the UK, BioPortfolio is well positioned to coordinate our customers' orders sourced from over 50 global report publishers.

We are pleased to present details of this report to assist your buying decision and administrative process. You will find easy-to-use *How To Buy* information on the last page of this document.

***We look forward to being of service to you.***

*If you have bulk and/or recurring requirements, please get in touch - we can liaise with publishers to obtain sample pages and negotiate discounts on your behalf.*

**Phone:** +44 (0)7887 945155 or **Email:** [pdb@bioportfolio.co.uk](mailto:pdb@bioportfolio.co.uk)

# Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Inhibitors -Pipeline Insights, 2017

DelveInsight's, "Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Inhibitors-Pipeline Insights, 2017", report provides in depth insights on the pipeline drugs and their development activities around the Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Inhibitors. The DelveInsight's Report covers the product profiles in various stages of development including Discovery, Pre-clinical, IND, Phase I, Phase II, Phase III and Preregistration. Report covers the product clinical trials information and other development activities including technology, licensing, collaborations, acquisitions, fundings, patent and USFDA & EMA designations details. DelveInsight's Report also provides detailed information on the discontinued and dormant drugs that have gone inactive over the years for Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Inhibitors. DelveInsight's Report also assesses the Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Inhibitors therapeutics by Monotherapy, Combination products, Molecule type and Route of Administration.

Please note: This report requires certain updates. We have all the information available but require 3 business days to complete the process and ensure it is as up-to-date as possible. Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated indication.

## Scope

- The report provides competitive pipeline landscape of Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Inhibitors
- The report provides pipeline products under drug profile section which includes product description, MOA, licensors & collaborators, development partner and chemical information
- Coverage of the Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Inhibitors pipeline on the basis of target, MOA, route of administration, technology involved and molecule type
- The report reviews key players involved in the therapeutics development for Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Inhibitors and also provide company profiling
- The report also gives the information of dormant and discontinued pipeline projects
- Pipeline products coverage based on various stages of development ranging from preregistration till discovery and undisclosed stages
- Provides pipeline assessment by monotherapy and combination therapy products, stage of development and molecule type

Delivery Time 48-72 Hours

## Additional Details

**Publisher** : Delve Insight  
**Reference** : DIMR2017577  
**Number of Pages** : 60  
**Report Format** : PDF  
**Publisher Information** :

**DELVEINSIGHT**  
INSIGHTS DRIVING PERFORMANCE

**BioPortfolio**  
Life Science Healthcare and Pharmaceutical  
Global Market Research and Corporate Data

**BioPortfolio**  
Life Science Healthcare and Pharmaceutical  
Global Market Research and Corporate Data

**BioPortfolio**  
Life Science Healthcare and  
Pharmaceutical  
Market Research and  
Corporate Data

**Best Prices  
Guaranteed**

**bioportfolio.co.uk**

DelveInsight is a leading Business Consulting and Market Research Firm. We combine industry expertise with probing market insights in innovative ways to deliver enduring results to deliver critical information to leading decision makers.

We help our clients to find answers relevant to their business, facilitating decision-making; identify potential market opportunities, competitor assessments and business environmental assessment. DelveInsight is a knowledge partner for business strategy and market research across the drug value chain.

# Table Of Contents for Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Inhibitors -Pipeline Insights, 2017 [Report Updated: 30-05-2017]

# List Of Tables in Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Inhibitors -Pipeline Insights, 2017 [Report Updated: 30-05-2017]

- Number of Products under Development for Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Inhibitors by Therapy Area, 2017
- Number of Products under Development for Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Inhibitors, 2017
- Number of Products under Development by Companies
- Comparative Analysis by Filed and Phase III Products, 2017
- Comparative Analysis Phase II Products, 2017
- Comparative Analysis Phase I and IND Filed Products, 2017
- Comparative Analysis Discovery and Pre-Clinical Stage Products, 2017
- Drug Candidates Profiles
- Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Inhibitors Assessment by Monotherapy Products
- Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Inhibitors Assessment by Combination Products
- Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Inhibitors Assessment by Route of Administration
- Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Inhibitors Assessment by Stage and Route of Administration
- Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Inhibitors Assessment by Molecule Type
- Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Inhibitors Assessment by Stage and Molecule Type
- Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Inhibitors Therapeutics – Discontinued Products
- Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Inhibitors Therapeutics – Dormant Products
- Products under Development by Companies, 2017

# List Of Figures, Charts and Diagrams in Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Inhibitors - Pipeline Insights, 2017 [Report Updated: 30-05-2017]

- Number of Products under Development for Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Inhibitors by Therapy Area, 2017
- Number of Products under Development for Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Inhibitors, 2017
- Filed and Phase III Products, 2017
- Phase II Products, 2017
- Phase I and IND Filed Products, 2017
- Discovery and Pre-Clinical Stage Products, 2017
- Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Inhibitors Assessment by Monotherapy Products
- Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Inhibitors Assessment by Combination Products
- Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Inhibitors Assessment by Route of Administration
- Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Inhibitors Assessment by Stage and Route of Administration
- Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Inhibitors Assessment by Molecule Type
- Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Inhibitors Assessment by Stage and Molecule Type



# How to Buy...

Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Inhibitors -Pipeline Insights, 2017 [Report Updated: 30-05-2017]

## Option 1 - Online

Go to our website and pay online with any major debit or credit card:

<https://www.bioportfolio.co.uk/product/85761>

## Option 2 - Request a Proforma Invoice

Fill in the details below, and either **Scan** this page **and email** it to us at [pdb@bioportfolio.co.uk](mailto:pdb@bioportfolio.co.uk) or **Fax** it to us at +44 (0)1305 791844. We will send you a Proforma Invoice and deliver your report on settlement.

**Your Name:** .....

**Job Title:** .....

**Your Email:** .....

**Your Contact Phone:** .....

**Company Name:** .....

**Address:** .....

**Post/Zip Code:** .....

**Country:** .....

**P.O. Number:** .....

**Any Other Instructions:** .....

**Pricing Options:** (please tick one)

- \$1250** | Single User Price
- \$2500** | Site License Price
- \$3750** | Enterprise License Price

**Payment Options:** (please tick one)

- Online Credit Card** (we will email you the invoice with a payment link)
- Direct Wire Transfer** (we will email you the invoice with our bank details)

**Authorising Signature:** .....

## Option 3 - Phone Us on +44 (0)7887 945155

We will be delighted to give you our personal attention.